We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Mawi DNA

Mawi DNA Technologies develops unique biosample collection technologies enabling universal sample collection from any... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Whole Blood Collection Technology Enables Isolation of cfDNA, CTC, and RNA from Same Sample

By LabMedica International staff writers
Posted on 03 Aug 2022
Print article
Image: HemaSure-OMICs collection tubes (Photo courtesy of Mawi DNA)
Image: HemaSure-OMICs collection tubes (Photo courtesy of Mawi DNA)

RNA is a crucial tool in advancing our understanding of health and disease in humans and animals. However, RNA is particularly fragile and degrades quickly as soon the cells leave the internal environment of the body, such as when blood is drawn. A reliable technology to stabilize the sample right after collection is needed to reduce the degradation rate and maintain RNA integrity for proper analysis. Currently, efficient stabilization of RNA in body fluids, cells or tissues requires expensive cold chain involvement or relatively toxic fixative, which increases the cost per sample and urgency for processing the sample, leaving very little room for error. Whole blood can be a great source of stable RNA. However, commercially available whole blood collection tubes for RNA stabilization have certain limitations. Now, a groundbreaking product for ambient collection, stabilization, and transportation of whole blood samples enables isolation of cfDNA, CTC, and RNA from the same sample. Collected cells are maintained intact, making them also suitable for FACS analysis.

In order to overcome existing hurdles and enable widespread and efficient collection and analysis of whole blood, Mawi DNA Technologies (Hayward, CA, USA) has developed the HemaSure-OMICs Collection Tube products that offer non-toxic stabilization of whole blood, free of formaldehyde or formaldehyde-like ingredients. HemaSure-OMICs Whole Blood Collection Tubes are validated for room temperature stabilization of viral DNA and RNA for several days in viral load and detection assays applicable to the HIV, MERS-CoV, 2019-nCoV and other DNA and RNA viruses.

cfDNA (up to 14 days), CTC (up to 8 days), and RNA (up to 8 days) are stabilized at room temperature in the same blood tube (temperature range of 25° – 45° C). HemaSure-OMICs Whole Blood Collection Tubes are available in 3, 6, and 9 mL plastic vacuum filled blood collection tubes as well as a 250µl microtainer for blood drops for easy shipping and durability. They are compatible with any commercially available manual or automation-enabled kits for the purification of cfDNA and CTC from whole blood. HemaSure-OMICs Whole Blood Collection Tubes are for research use only and not for use in diagnostic or therapeutic procedures.

Related Links:
Mawi DNA Technologies

Platinum Supplier
Respiratory Virus Multiplex Test
Respiratory Virus 12 Types Nucleic Acid Detection Kit
Automatic Fecal Analyzer
Hemoglobin A1c Control
HbA1c (Auto)
Capillary Electrophoresis System

Print article
IIR Middle East



view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.